Fubotv earnings beat by $0.10, revenue topped estimates
Rajeev Singh, the Chief Executive Officer of Accolade, Inc. (NASDAQ:ACCD), recently sold shares of the company’s stock. According to a recent SEC filing, Singh sold 289 shares at a price of $6.985 per share on March 18, 2025, totaling approximately $2,018. This transaction was conducted to cover tax withholding obligations related to the vesting of performance-based restricted stock units. The sale comes as Accolade, currently valued at $574 million, shows strong momentum with a 67% price return over the past six months. InvestingPro analysis indicates the stock is currently undervalued, with a GOOD overall financial health score.
In addition to the sale, Singh acquired 933 shares of common stock through the conversion of restricted stock units on March 17, 2025. This transaction did not involve any cash exchange. Following these transactions, Singh holds 829,090 shares directly and an additional 651,619 shares indirectly through Avanti Holdings, LLC, where he exercises voting and investment power. Get deeper insights into Accolade’s valuation metrics and 8 additional key ProTips with InvestingPro’s comprehensive research report.
In other recent news, Accolade Inc . has announced its acquisition by Transcarent in a deal valued at $621 million, with shareholders receiving $7.03 per share. This represents a 110% premium over the company’s closing stock price before the announcement. The acquisition, expected to close in the second quarter of 2025, will see Accolade become a privately held company and its stock delisted from Nasdaq. Following the merger, Accolade will integrate its healthcare platform with Transcarent’s offerings, aiming to enhance access to high-quality healthcare and reduce costs.
Meanwhile, Stifel analysts downgraded Accolade’s stock from Buy to Hold, adjusting the price target to $7.03, reflecting a cautious stance on the company’s future performance. Raymond (NSE:RYMD) James also adjusted its rating from Outperform to Market Perform, citing the acquisition’s valuation and its alignment with revenue and EBITDA estimates for the fiscal year 2026. On a more optimistic note, Truist Securities maintained a Buy rating on Accolade, with a price target of $7.50, highlighting the synergistic potential of the merger with Transcarent.
The transaction will be financed through equity financing led by General Catalyst and 62 Ventures. Accolade has withdrawn its previous financial guidance for the fiscal year, although it plans to file its Form 10-Q for the third quarter and report financial results within the previously provided range.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.